Posted on

Albert Labs Appoints Two Industry Leading Director

Albert Labs Appoints Two Industry Leading Director

Albert Labs welcome Mike Thompson, MBE and Katie Shelton-Innes to the Board of Directors 

July 11th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the “Company”), a pharmaceutical drug development company focussed on gaining regulatory approval for active compounds from natural sources to address mental health disorders, is pleased to announce the appointment of Mike Thompson MBE and Katie Shelton-Innes to its Board.

Mike Thompson, MBE joins Albert Labs as a prominent figure in Healthcare and Pharmaceuticals, bringing twenty-five years of experience in the Life Sciences sector. Between 2016 and 2019, Mike served as CEO at The Association of the British Pharmaceutical Industry (ABPI) and previously held senior positions at GSK in Global, European Regional and UK levels of the company. In 2021 Mike was awarded an MBE for services to medicines supply and resilience in the Queen’s Birthday Honours List.

During his time as CEO at the ABPI, Mike was at the forefront of UK drug approval and pricing policy, working hand-in-hand with Government bodies on behalf of the pharmaceutical industry. Amongst a number of considerable achievements in this role, Mike oversaw the agreement for £60bn of expenditure on branded pharmaceuticals, working closely with 10 Downing Street, HM Treasury and the Department of Health and Social Care.

Mike Thompson, MBE said: “Whilst enormous progress has been made in recent years in prolonging life for many cancer patients, both clinicians and the life sciences industry are well aware of the significant gap that still remains in alleviating related mental health distress. I’m delighted to be joining Albert Labs to help them bring their KRN-101 asset to market.”

Katie Shelton-Innes is well-known in the United Kingdom for her work advising and raising funds for growth companies. She has a wealth of experience working for full-service investment banks, focussing on small to mid-cap companies, and was Head of Corporate Brokering at Arbuthnot Banking Group and Northland Capital Partners.

Katie brings an astute knowledge of financial markets and a broad range of subsequent experiences and relationships. She joins the Albert Labs Board at a fitting time with the company exploring a listing in the United Kingdom while simultaneously scaling its operational functions across the UK, Canada and Portugal. Her appointment will consolidate the company’s presence in the UK financial markets and support the company with its strategy for generating value for investors.

Katie Shelton-Innes said: “I am pleased to join Albert Labs at this pivotal time for the company, seeking to extend the strong progress that has already been made both from a financial and operational perspective. My experience will assist the company in consolidating its position in the UK market and ultimately support its pursuit of a public listing here. I’m looking forward to working closely with the Board to meet their rightly ambitious targets for the company as it continues its important work in the treatment of mental health.”

Dr. Michael Raymont, CEO of Albert Labs, said: “I am delighted to have Katie and Mike join us as Board Directors at Albert Labs. Their experience and connections will be invaluable to the company as we progress through our clinical trial and beyond. Assuming our trial is successful, and we have every expectation that it will be, then market access, pricing, reimbursement, supply chain expansion and additional growth capital to fund our evolution, will be issues with which our Board has to deal. I would like to thank Richard and Frank, who will be leaving the Board, for their contributions and wish them every success with their future endeavours.”

Business of Albert Labs

Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds from natural sources, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with its regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet.  Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized clinical access route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. 

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to their treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

The company’s goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.

Albert Labs (CSE: ABRT) (FSE: VB50) is listed on the Canadian Securities Exchange (CSE) and uses patent-pending technology to manufacture natural psilocybin Active Pharmaceutical Ingredients (API). Albert Labs is progressing swiftly through confirmatory toxicology studies a work programme that will provide essential data on Albert Labs’ product in support of clinical trials due to start later this year. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here (https://youtu.be/otQezIvmIXI).

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

Posted on

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming Real World Evidence Study on KRN-101

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming Real World Evidence Study on KRN-101

May 26th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (Albert Labs (CSE: ABRT) (FSE: VB50), the “Company”), an R&D company developing mental health therapeutic medicines, is pleased to announce Dr. Sara Tai, Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America.

Dr. Tai has extensive clinical research experience, having developed psychological interventions for people diagnosed with a variety of mental health issues such as depression, psychosis and bipolar disorder. Her research focuses on the science and practice of therapy, progressing these into regulatory approved clinical practices. In addition to developing these structures and practices, Sara has a deep understanding of the commercial imperative of delivering the necessary training to offer these novel therapeutics at scale as part of the UK’s National Health Service.

Dr. Malcolm Barratt-Johnson, Albert Labs’ Chief Medical Officer, said, “I’m delighted that Dr.  Tai has agreed to work with Albert Labs as Principal Investigator in what will be the company’s key first study investigating the effects of a natural psilocybin treatment on cancer-related distress. Sara is rightly regarded as a leading global light in the field of psilocybin research, having been involved in several of the studies underpinning our present knowledge in this important area of clinical research.” 

“I am thrilled to be working with Albert Labs, who are committed to addressing the mental health needs of people with cancer, a significant area of unmet need. I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy assisted by novel plant-based medications. Being involved in such groundbreaking research with the potential to develop new treatments for people in great need is very exciting”, added Dr. Sara Tai.  Listen more to what Dr Tai had to say in a recent interview. 

Business of Albert Labs

A clinical research and drug development enterprise, Albert Labs and its team of experts leverage advanced culture technology and natural extraction to accelerate the development of highly effective mental health medicines. Albert Labs uses an approved, fast track regulatory pathway known as Real World Evidence (RWE). RWE studies are increasingly recognized as a valuable regulatory approval process, which was used in the successful development of Covid-19 vaccines. This accelerated development pathway will facilitate Albert Labs in delivering on its goal of receiving market authorization and creating safe and effective licensed medicines. 

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

Albert Labs (CSE: ABRT) (FSE: VB50) is listed on the Canadian Securities Exchange (CSE) and uses patent-pending technology to manufacture natural psilocybin Active Pharmaceutical Ingredients (API). Albert Labs is progressing swiftly through confirmatory toxicology studies a work programme that will provide essential data on Albert Labs’ product in support of clinical trials due to start later this year. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here (https://youtu.be/otQezIvmIXI).

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

Posted on

Albert Labs Granted Health Canada Licence

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

May 16th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the “Company”), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada. This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

At the company’s research and production facility, Albert Labs cultivate, extract, and process pharmaceutical-grade natural psilocybin. Utilizing patent-pending technology, Albert Labs can optimize the consistency and standardization of natural psilocybin Active Pharmaceutical Ingredients (APIs) to meet regulatory compliance standards. With the issue of this license, Albert Labs has the ability to distribute API to Canada and, where import licenses exist, internationally. The licence will allow Albert Labs to supply product to its forthcoming Real World Evidence (RWE) trial in the UK, as well as distribute and sell API to other licensed customers. Under the Special Access Program (SAP) in Canada, Albert Labs is also able, once a medicinal product is approved, to provide health care professionals with medicines under prescribed conditions.

“This is an important milestone for Albert Labs; it firms up our supply chain and provides us with more market opportunities,” said Dr. Michael Raymont, CEO. He continued, “We have spent significant effort to develop our production technology, allowing us to cultivate and process the most consistent natural pharmaceutical psilocybin products in the industry. With this license, we now have the flexibility to produce and supply precursor APIs to our own operations in Europe and to explore sales to other customers in Canada and elsewhere.” Listen more to what Dr. Michael Raymont had to say here.

Dr. Raymont also endorsed Health Canada for its leadership in creating a favourable regulatory environment for advancing therapeutic uses for psilocybin. Dr. Raymont added, “The Canadian Government has created a beneficial environment for business to develop psychotherapeutic prescription drugs, which have the potential to help millions of sufferers with anxiety, depression and other mental health indications. Mental health issues can ruin lives, wreck families, and cost economies billions in lost productivity. It’s inspiring to see Canada as a leader in mental health R&D and treatments.”

Business of Albert Labs

Albert Labs is a clinical research and drug development enterprise, and its team of experts leverage advanced culture and extraction technologies to accelerate the development of effective mental health medicines. Through collaborations with research institutions, hospitals and government agencies, and by the use of expedited regulatory approval pathways, Albert Labs is able to rapidly assess candidate products for their potential as licensed medicines in the treatment of mental health illnesses.

Albert Labs’ first product, KRN-101, is believed to act on 5-HT2A receptors and is being investigated as a potential treatment for cancer-related anxiety. With over 15 million people thought to suffer from the condition and approximately 1 million new sufferers diagnosed each year, cancer-related distress represents an urgent and unmet need in mental health treatment. From this initial focus, Albert Labs will address broader mental health disorders, reported to affect over a billion people worldwide.

Albert Labs (CSE: ABRT) (FSE: VB50) recently executed a listing on the Canadian Securities Exchange (CSE) and filed a provisional patent for the scalable production of natural psilocybin medicine. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.
The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

Posted on

Albert Labs’ Pre-Clinical Analytical And Toxicological Research Supports Company’s Forthcoming Studies

Albert Labs’ Pre-Clinical Analytical And Toxicological Research Supports Company’s Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs’ expert team to conduct safety and toxicology studies, in preparation for KRN-101’s use in Real World Evidence studies.

May 12th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the “Company”), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal. The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs’ mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

These pre-clinical studies, led by distinguished toxicologist, Dr. Ricardo Jorge Dinis-Oliveira, help to clarify the toxicological, pharmacokinetic and pharmacodynamic properties of Albert Labs’ proprietary mycelium derived Active Pharmaceutical Ingredients (API). All preclinical work is conducted under Good Laboratory Practice (“GLP”) guidelines and, through the OECD’s Mutual Acceptance of Data scheme, will be accepted by leading health regulators such as the FDA and EMA. This data is needed prior to the commencement of Albert Labs’ Real World Evidence (RWE) clinical trial with its first product candidate, KRN-101.

Dr. Michael Raymont, CEO of Albert Labs, said, “Our partnership with Dr. Ricardo and his expert team is important, not just for our first candidate, KRN-101, but also for all Albert Labs’ future product developments. Preclinical studies such as these are a crucial step for any drug development cycle and through this collaboration, we have been able to bring this capability and value in-house. It adds to our skill set as an “end-to-end” drug development company”. Listen more to what Dr. Michael Raymont had to say here.

Dr. Ricardo Jorge Dinis-Oliveira said, “The team and I are honoured to be working with Albert Labs. We have strong alignment with their goals and we will ensure that their investigational product KRN-101 meets all the necessary safety evaluations prior to administering it to patients in their upcoming trial. We also expect to publish the outcomes of our work and bolster the already abundant safety data available in published literature surrounding psilocybin”.

Business of Albert Labs

Albert Labs is a clinical research and drug development enterprise, and its team of experts leverage advanced culture and extraction technologies to accelerate the development of effective mental health medicines. Through collaborations with research institutions, hospitals and government agencies, and by the use of expedited regulatory approval pathways, Albert Labs is able to rapidly assess candidate products for their potential as licensed medicines in the treatment of mental health illnesses.

Albert Labs’ first product, KRN-101, is believed to act on 5-HT2A receptors and is being investigated as a potential treatment for cancer-related anxiety. With over 15 million people thought to suffer from the condition and approximately 1 million new sufferers diagnosed each year, cancer-related distress represents an urgent and unmet need in mental health treatment. From this initial focus, Albert Labs will address broader mental health disorders, reported to affect over a billion people worldwide.

Albert Labs (CSE: ABRT) (FSE: VB50) recently executed a listing on the Canadian Securities Exchange (CSE) and filed a provisional patent for the scalable production of natural psilocybin medicine. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.
The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

Posted on

Albert Labs Announces the Addition of Two Renowned Scientific Advisors to its Scientific Advisory Board (SAB)

Albert Labs Announces the Addition of Two Renowned Scientific Advisors to its Scientific Advisory Board (SAB)

Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira bring drug development and pharmacology/toxicological expertise to Albert Labs’ expanding R&D and Prescription Medicine activities

April 26th 2022 – VANCOUVER, BRITISH COLUMBIA

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), or the “Company”, a mental health research and drug development company have strengthened their Scientific Advisory Board, with the addition of Professor Robert Britton, a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira.

Professor Robert Britton, BSc, PhD, of Simon Fraser University, is a well-published natural product chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry, and cancer therapeutics. With a particular focus on oncology, Prof. Britton creates new tools for late-stage modification of drug leads, new processes for improving the manufacture of drugs, and new strategies for synthesizing structurally complex natural products. Prior to his academic career, Prof. Britton was a Senior Scientist in the Process Research Group at Merck.

Dr. Ricardo Jorge Dinis-Oliveira, PhD, European PhD, DSc, is an expert Toxicologist and Pharmacologist. His scientific and academic focus is in the areas of toxicology and the pharmacology of psychoactive substances and medicines, focusing on their preclinical, and clinical development stages. He is a member of the editorial boards and ambassador to several international scientific journals. Dr. Dinis-Oliveira is extremely well-published, having authored more than 170 published articles in international indexed journals and peer-reviewed, and acted author of some thirty-six book chapters, four books and four national and three international patents. In 2021 he was included on the world’s top 2% of Scientists List, which ranks the most highly cited scientists globally. He has a passion for the pharmacology of psychoactive substances and has recently taken on the position of Editor-in-Chief of the newly formed journal, “Psychoactives”, an international, peer-reviewed, journal on psychoactive substances.

Dr. Michael Raymont, CEO of Albert Labs, said, “We are delighted to welcome Professor Robert Britton and Dr. Dinis-Oliveira to our Scientific Advisory Board (SAB). Their exceptional expertise in natural product medicines and their depth of knowledge in toxicology and pharmacology complement the expertise of our other SAB members. Improving drug discovery, and gaining a better understanding and depth of these compounds’ pharmacodynamics and toxicology are critical to building value for Albert Labs shareholders as we advance toward our goal of delivering safe and effective drugs to revolutionize mental health treatment.”

Professor Robert Britton added, “I’m excited to be working with Albert Labs. Fungi have been an important source of new medicines and are, on the whole, pharmaceutically prolific and extremely promising. Albert Labs’ scientific approach to natural product drug discovery and development is a promising step towards the creation of new medications for patients with urgent unmet needs and developing a future pipeline of products for wider indications.”

Dr. Dinis-Oliveira said, “My team and I will complete thorough toxicological & pharmacological testing to ensure that all of Albert Labs’ clinical work, with KRN-101, is delivered safely and effectively. I am looking forward to assisting a company that will be safely administering psilocybin as a complement to psychotherapy and other pharmacological chemical treatments for people with urgent and unmet needs. This is especially the case for patients who are refractory to conventional treatments.”

Business of Albert Labs

A clinical research and drug development enterprise, Albert Labs and its team of experts leverage advanced culture technology and natural extraction to accelerate the development of highly effective mental health medicines. Albert Labs look to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized pathway heavily used in the successful development of Covid-19 vaccines. This accelerated development pathway will facilitate Albert Labs in delivering on its goal of receiving Market Authorization and creating highly successful, licensed medicines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to their treatment. Albert Labs’ medicinal product, KRN-101, is being developed as a potential solution for cancer-related distress, a market of over 15 million people with some 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

Albert Labs (CSE: ABRT) (FSE: VB50) recently completed a listing on the Canadian Securities Exchange (CSE) and filed a provisional patent for the scalable production of natural psilocybin medicine. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Cautionary Statement

This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.

The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.

Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities laws.

Posted on

Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species

Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species

MARCH 30th 2022 – VANCOUVER, BRITISH COLUMBIA
Albert Labs International Corp. (CSE: ABRT), (FSE: VB50) (the “Company”), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines, based on mycelia of Psilocybe and other fungi, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a proprietary process. Albert Labs’ culturing process can significantly increase the production volumes of psilocybin medicine. The Company sees the demand for naturally produced psilocybin continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide.

The improved quality and consistency enabled by this patent-pending process are paramount to scaling the Eu-GMP production of psilocybin Active Pharmaceutical Ingredient (API). The new process and methodology optimized key parameters necessary for the efficient cultivation that results in an increased high-quality yield of Psilocybe mycelia. The same patent-pending process and methodology can also be applied to the optimized cultivation of other fungi species, opening up the untapped potential market of bio-active fungal compounds. This is not a synthetic or biosynthetic process and does not use or introduce harmful synthetic chemicals or genetically modified bacteria in the production of psilocybin. Batch to batch, Albert Labs’ bioreactor design allows them to produce strong yields of consistent psilocybin API, which will continue to be assessed for clinical efficacy and safety through Albert Labs’ upcoming real-world evidence trials.

“At Albert Labs, we focus on the science of producing and extracting natural product pharmacologically bioactives for mental health. Today’s announcement is a testament to the R&D and engineering expertise we have on our team. Albert Labs’ manufacturing technology breakthrough represents a very significant step forward in our production capabilities for pharmaceutical-quality psilocybin with consistent and standardized psychoactive properties. API consistency is critically important for regulatory approval, and unfortunately, many “field grown” natural substances are too variable for pharmaceutical usage. While a massive body of science dating back many centuries suggests that natural products can have major medicinal benefits, “crop-to-crop” variability has been a severe drawback for their use in regulated pharmaceuticals for many decades. Using this new Albert Labs’ technology, the consistent quality of our API is a significant step forward to delivering our first trial drug, KRN-101, to patients and thus to treating millions of suffers with unmet mental health needs.” Added Dr Michael Raymont, Chief Executive Officer.

“The newly filed patent-pending process and methodology was painstakingly developed at Albert Labs using rigorous scientific methods. For the first time, scalable production of Psilocybe mycelia using an all-natural process, can be used to address the ever-increasing demand from global markets”, said Parminder Singh, head of Albert Labs’ Scientific Advisory Board.

Business of Albert Labs
A clinical research and drug development enterprise, Albert Labs and its team are experts at producing and extracting natural drug candidates. Albert Labs looks to develop solutions to the mental health epidemic through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognized pathway heavily used in the successful development of Covid-19 vaccines. This accelerated development pathway will facilitate Albert Labs in delivering on its goal of receiving market authorization and creating highly successful, licensed medicines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to their treatment. Albert Labs’ first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

Albert Labs recently executed a listing on the Canadian Securities Exchange (CSE) under the ticker ABRT. You can find more details at albertlabs.com or watch a short “About Albert Labs” video here.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs International Corp.

Dr. Michael Raymont

Chief Executive Officer & Chairman

For further information please contact:
Email: press@albertlabs.com
Website: albertlabs.com
Tel: +1 778-819-0740

Cautionary Statement
This news release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this news release that are not purely historical are forward-looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs, or expectations regarding the future. Although the Company believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate.
The Company cautions readers that all forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their evaluation of such risks and uncertainties and should not place undue reliance on forward-looking statements.
Any forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual events or results could or do differ from those projected in the forward-looking statements. The Company assumes no obligations to update any forward-looking statements, whether as a result of new information, future events, or otherwise unless required by the applicable securities law

Posted on

Why the UK is becoming a psychedelic hotspot

Brexit Britain becomes unlikely psychedelic haven as Albert Labs IPOs

The UK is on a mission to create a world-leading clinical research ecosystem that’s more efficient and effective than ever before – and many psychedelic companies are taking advantage of the regulatory changes.

To reach this goal, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) now allows “real world data” (data collected from patients and healthcare systems outside of clinical trials) to aid in the drug approval process

This may bring psychedelic therapies to market much faster not only in the UK, but also in Australia, Canada, Singapore and Switzerland, as the MHRA joined a coalition with these countries called the Access Consortium.

Additionally, the UK may reschedule psilocybin to Schedule 2, reducing barriers to clinical research.

Just yesterday, COMPASS Pathways (CMPS) announced a strategic partnership to launch a major psychedelic research center in the UK.

Other companies to keep an eye on that may benefit from these changes include Albert Labs (ABRT), Awakn Life Sciences (AWKN), Small Pharma (DMT), Beckley Psytech, Eleusis.

PDF of article

PDF of article 2

Posted on

MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway

MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway

JANUARY 4, 2022 – VANCOUVER, BRITISH COLUMBIA

On the 17th December 2021 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) produced guidance acknowledging and setting out the criteria for the use of Real World Data and Evidence in regulatory decision making. This guidance is consistent with Albert Labs’ strategy, one of the first psychedelic drug development companies to use a Real World Evidence (RWE) approach for regulatory approval.

Albert Labs is pursuing the RWE pathway in the licensing of their natural psilocybin medicine, which has been endorsed by leading hospital centers in the UK. This expedited pathway offered by the UK regulatory system will accelerate access to treatment, benefiting patients not only in the UK but the rest of Europe, Canada, and the US.

“We embrace this regulatory guidance particularly in the investigation of psilocybin-assisted psychotherapy. Albert Labs consider that carefully designed pragmatic trials that implement a progressive use of Real World Evidence, will greatly advance the understanding of the safety, effectiveness, impact, and optimal clinical use of this new therapy.,” said Dr. Malcolm Barratt-Johnson, the Chief Medical Officer of Albert Labs.

The guidance emphasizes that a study or studies considered under this RWE approach, need to be of the same standard as would be expected from a traditional Randomized Control Trial (RCT). The guidance further states that well-designed and conducted prospective RCTs provide a high level of evidence irrespective of the categorization of the data source.

“Our approach, in the investigation of psilocybin-assisted therapy, has been designed to reduce risk, improve outcomes, and importantly to speed up access to those patients who will benefit from this therapy. We believe Real World Evidence will play a vital role in helping safeguard the development of this promising mental health treatment,” added Dr. Malcolm Barratt-Johnson.

Albert Labs, in following the MHRA’s guidance is taking the necessary regulatory and clinical steps required for authorization of a new treatment using an RWE approach. The trials are focused on early access to treatment. Albert Labs expects to treat patients suffering from cancer-related distress in the first half of 2022 with this focused approach and accelerated product development and licensing pathway.

ON BEHALF OF THE BOARD OF DIRECTORS

Albert Labs Inc.

Dr Michael Raymont

Chief Executive Officer

_______________________

About Albert Labs Inc.

A laboratory-based, clinical research and drug development enterprise. Albert Labs and its team are experts at the production and extraction of natural compounds and creating licensed medicines. Through a succinct clinical pathway, focusing on Real World Evidence (RWE) Albert Labs will initially look to commercialize its mycelium-based KRN-101 medicine & treatment, and in doing so deliver psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs put patients with urgent and unmet needs first as it develops licensed medicines to treat a variety of mental health conditions. Cancer-related distress, an initial focus of Albert Labs development program is thought to affect over 1 million patients in the UK.

[1] Read the MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions here. 

Listen to Albert Labs’ Chief Medical Officer, Dr. Malcolm Barratt-Johnson introduce Albert Labs and their mission here.

Watch a short “About Albert Labs” video and hear more of the investment opportunity here._______________________

Cautionary Statement

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties.  Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, beliefs or expectations regarding the future.  Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate.

The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements.  Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements.

Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements.  The Company assumes no obligations to update any forward looking statements, whether as a result of new information, future events or otherwise unless required by the applicable securities laws.

SOURCE Albert Labs Inc.

For further information: Email: press@albertlabs.com.i

Posted on

A better solution for cancer patients

B.C.’s functional and psychedelic mushroom industry is having a shroom boom

Antidepressants are often ineffective and can even interfere with cancer treatment drugs.

“Psychedelics are proving to not conflict with the cancer drug and are more effective than normal antidepressants generally,” according Frank Lane, director of Albert Labs. 

That’s why the BC-based company wants to bring a psilocybin treatment for cancer patients to European markets.

Albert Labs is expected to begin trading on the CSE early next year under the ticker ’ABRT’.

PDF of article